This is the first FDA-approved antimicrobial catheter lock solution. The FDA has approved taurolidine plus heparin (DefenCath®) catheter lock solution to reduce catheter-related bloodstream infections ...
Several randomized clinical trials with short-term follow-up have shown that patients on hemodialysis with prophylactic antibiotic catheter locks have reduced catheter-related bacteremia. However, the ...
Please provide your email address to receive an email when new articles are posted on . BOSTON — Neutrolin, an investigational new drug containing taurolidine, was shown to reduce catheter-related ...
The Food and Drug Administration (FDA) has approved DefenCath ® (taurolidine and heparin) catheter lock solution to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results